Clinical trials: Diabetes Type II
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)
This trial is conducted in Asia. The aim of this trial is to confirm the efficacy of insulin degludec/liraglutide in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral…
- Trial name
- DUAL™ I China (NCT03172494)
- Testing
- Insulin degludec/liraglutide, Insulin degludec, Liraglutide
- Where
- 36 sites in China
- Volunteers
- 720 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus, Cardiovascular Disease
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
This study is carried out to assess whether dapagliflozin improves glycemic control, decreases fasting plasma glucose levels, body weight and blood pressure when added to patient's existing medications and how it compares with…
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Disease, Inadequate Glycaemic Control
- Trial name
- NCT01042977
- Testing
- Dapagliflozin
- Where
- 135 sites in United States, Argentina and 8 more
- Volunteers
- 964 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans
The purpose of this study is to investigate the acute effects of the thiazolidinedione agent pioglitazone (which has combined PPAR alpha and gamma stimulation) on insulin's ability to suppress glucose production, stimulated…
- Trial name
- NCT00179400
- Testing
- Pioglitazone, Pancreatic Clamp Study
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Albert Einstein College of Medicine
Type 2 Diabetes Mellitus
A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)
This study will evaluate whether the addition of Sitagliptin treatment provides a greater decrease in A1C levels compared to placebo in participants with inadequate glycemic control on sulfonylurea and metformin combination…
- Trial name
- NCT01076075
- Testing
- Sitagliptin phosphate, Comparator: pioglitazone, Glimepiride or gliclazide
- Volunteers
- 427 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Kidney Disease, Type 2 Diabetes Mellitus
A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes.
- Trial name
- NCT01847092
- Testing
- AZD1722
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Ardelyx
Type 2 Diabetes
My Diabetes Study - CGM Initiation Approach & Time In Range
This study includes two phases. The purpose of Phase 1 of this study is to understand if there is a difference between two ways of introducing a continuous glucose monitor (CGM) to people with type 2 diabetes (T2D).
- Trial name
- NCT05928572
- Testing
- CGM initiation approach
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Holly Willis
Diabetes Mellitus, Type 2, Kidney Failure, Chronic
Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy
The primary purpose of this study is to test the effectiveness and tolerability of Niaspan® to improve the levels of blood fats ("good" and "bad" cholesterol and triglyceride levels) in people who have kidney damage due to…
- Conditions
- Diabetes Mellitus, Type 2, Kidney Failure, Chronic, Hyperlipidemia
- Trial name
- NCT00108485
- Testing
- Extended release niacin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Miami
CKD, Diabetic Kidney Disease
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or…
- Conditions
- CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity
- Trial name
- RAISE-KT (NCT04741074)
- Testing
- Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Geisinger Clinic
Type 2 Diabetes
Comparison Effects Of Different Exercise Approaches On Type 2 DM Women
Type 2 Diabetes Mellitus (T2DM) is one of the most common metabolic diseases with a complex, multifactorial etiology, and is a chronic disease with various clinical and biochemical manifestations.
- Trial name
- NCT05479435
- Testing
- Blue Prescription Exercise Program, Video Based Home Exercise Program, Supervised Group Exercise Program
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Istanbul Medipol University Hospital
Periodontal Disease, Type 2 Diabetes Mellitus
Relationship of Periodontal Disease Treatment and Type 2 Diabetes Mellitus in the Gullah Population
Our overall hypothesis is that treatment of periodontal disease will produce better diabetes glycemic control (glycated hemoglobin A1c, or HbA1c) and reduced levels of the catalytically active form of matrix metalloproteinase…
- Trial name
- NCT01798225
- Testing
- Doxycycline
- Volunteers
- 113 people
- Sponsor
- Medical University of South Carolina
Healthy, Obese
Exercise Regulation of Human Adipose Tissue
The purpose of this study is to determine whether exercise training leads to changes in the white adipose tissue that are beneficial to the body's regulation of sugar and body weight.
- Conditions
- Healthy, Obese, Diabetes Mellitus, Type 2
- Trial name
- NCT03133156
- Testing
- Exercise Intervention
- Where
- United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Joslin Diabetes Center
Diabetes Mellitus, Type 2
Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans
The SUGAR-MGH investigators are studying the influence of inherited gene variants on the response to two commonly prescribed type 2 diabetes medications, metformin and glipizide.
- Trial name
- SUGAR-MGH (NCT01762046)
- Testing
- Glipizide, Metformin, Oral Glucose Tolerance Test
- Where
- 3 sites in United States
- Volunteers
- 1,033 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Managing Type 1 and High Risk Type 2 Diabetes in the Hospital Setting: Glucose as a Vital Sign
This program will provide patients with type 1 and high risk type 2 diabetes the safest hospitalization by using wireless continuous glucose monitoring devices (CGM) to track their glucose parameters in real-time similar to other…
- Trial name
- CGM (NCT03068273)
- Testing
- Real-time CGM data
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- Scripps Whittier Diabetes Institute
Diabetes Mellitus, Type 2
A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise
The purpose of this study is to assess the effectiveness of the co-administration of canagliflozin and metformin extended release (XR) compared with canagliflozin alone, and metformin XR alone in patients with type 2 diabetes…
- Trial name
- NCT01809327
- Testing
- Canagliflozin 100 mg, Canagliflozin 300 mg, Metformin XR
- Where
- 129 sites in United States, Argentina and 11 more
- Volunteers
- 1,186 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes Mellitus
Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010) in comparison to placebo, as an add-on treatment to metformin with or without sulfonylurea, over a period of 24 weeks of treatment.
- Trial name
- GetGoal-M-Asia (NCT01169779)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Metformin
- Where
- 35 sites in China, Hong Kong and 2 more
- Volunteers
- 391 people
- Sponsor
- Sanofi
COVID-19
Impact of COVID-19 on Marshallese Communities in the U.S.
Marshallese adults in the U.S. will complete an online or telephone survey. This survey will collect data describing the impact of COVID-19 on Marshallese communities.
- Trial name
- NCT04474496
- Testing
- Assessing the impact of COVID-19
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Arkansas
Diabetes Mellitus, Type 2
A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients
This study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK2330672 compared to sitagliptin when administered with metformin for 14 days to subjects with type 2 diabetes…
- Trial name
- NCT02202161
- Testing
- GSK2330672, Sitagliptin, Metformin
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)
This is a study of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-8666 in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01971554
- Testing
- MK-8666
- Volunteers
- 63 people
- Sponsor
- Merck Sharp & Dohme LLC
Metabolism and Nutrition Disorder, Obesity
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin.
- Trial name
- SCALE™ Insulin (NCT02963922)
- Testing
- Liraglutide 3.0 mg
- Where
- 54 sites in United States, Canada and 5 more
- Volunteers
- 396 people
- Sponsor
- Novo Nordisk A/S
Type2 Diabetes, Kidney Diseases
GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes
This is a prospective study to evaluate effect of Exenatide extended release treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to placebo.
- Trial name
- 1981 (NCT03029351)
- Testing
- Exenatide Extended Release for Inj Susp 2 MG
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University at Buffalo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.